News | Radiation Therapy | May 20, 2019

Partial Breast Irradiation Effective, Convenient Treatment Option for Low-Risk Breast Cancer

New clinical data shows certain patients get similar results with five days of consecutive targeted treatment versus four to six weeks

Partial Breast Irradiation Effective, Convenient Treatment Option for Low-Risk Breast Cancer

May 20, 2019 — Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early-stage breast cancer, according to new clinical data. The data was derived from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).

This randomized, phase 3 study compared whole breast irradiation with partial breast irradiation in a large group of women with stage 0, 1 or 2 breast cancer. More than 4,200 patients were enrolled in the trial as part of NRG Oncology cooperative group clinical trial.

Study results showed that while partial breast irradiation does not produce equivalent cancer control for all breast cancer patients with stage 0, 1 and 2 disease, it should still be considered as an alternative for women with DCIS (ductal carcinoma in situ) and early-stage breast cancers deemed “low risk,” based on other tumor characteristics.

When looking at the entire study population, women who received partial breast irradiation experienced a 4.6 percent recurrence rate. Those who underwent whole breast irradiation experienced at 3.9 percent rate of recurrence. Toxicity from treatment was similar, as well as the risk for secondary cancers.

However, researchers also looked at how this played out in subsegments of the population and found that rates of recurrence were nearly identical for women with DCIS, regardless of whether they received whole or partial breast irradiation. This was also true for women with breast cancer classified as low-risk, based on the American Society for Radiation Oncology (ASTRO) clinical guidelines.

Researchers showed that in this subsegment of breast cancer patients, the likelihood of recurrence 10 years post-treatment was very low overall and almost identical between women who received whole breast irradiation (2.3 percent) and partial breast irradiation (2.7 percent).

Julia White, M.D., co-principal investigator of the national trial and head of breast radiation oncology at the OSUCCC – James said this is very important because it reduces the burden of care for women who can still achieve cancer control with fewer treatments, over a shorter period of time.

“A significant portion of the breast cancer patient population nationally – about 25,000 to 30,000 women — would qualify for partial breast irradiation. This is tremendously important because it allows us to give women the right amount of treatment for her disease, and potentially allowing better access to effective breast conservation for those who live far from a radiation facility. Partial breast irradiation can also be delivered in five consecutive days versus whole breast, which can involve four to six consecutive weeks of multi-day treatment. There is no denying that the five day treatment is less costly and disruptive to life,” said White.

At the OSUCCC – James, breast radiation is also delivered in the face down (prone) position to reduce radiation exposure in the chest wall, which has been linked to increased risk of heart and lung disease post cancer treatment.

Data from this NRG Oncology study will be presented at the 2019 American Society of Clinical Oncology Annual Meeting, May 31-June 4 in Chicago.

Watch the VIDEO: Whole Versus Partial Radiotherapy for Breast Cancer

For more information: www.cancer.osu.edu

 

Reference

1. Ganz P.A., Cecchini R.S., White J.R., et al. Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer. Presented at ASCO 2019. J Clin Oncol 37, 2019 (suppl; abstr 508)

Related Content

Some Pregnant Women Are Exposed to Gadolinium in Early Pregnancy
News | Women's Health | August 20, 2019
A small but concerning number of women are exposed to a commonly used magnetic resonance imaging (MRI) contrast agent...
First GammaTile Therapy Case Completed in Arizona
News | Radiation Therapy | August 19, 2019
HonorHealth Scottsdale Osborn Medical Center is the first hospital in Arizona to begin offering GammaTile Therapy, a...
Lunit Receives Korea MFDS Approval for Lunit Insight MMG
News | Artificial Intelligence | August 19, 2019
Lunit has announced Korea Ministry of Food and Drug Safety (MFDS) approval of its artificial intelligence (AI) solution...
ADHD Medication May Affect Brain Development in Children

Images of regions of interest (colored lines) in the white matter skeleton representation. Data from left and right anterior thalamic radiation (ATR) were averaged. Image courtesy of C. Bouziane et al.

News | Neuro Imaging | August 16, 2019
A drug used to treat attention-deficit/hyperactivity disorder (ADHD) appears to affect development of the brain’s...
Drug Accelerates Blood System's Recovery After Radiation, Chemotherapy

Following radiation, the bone marrow shows nearly complete loss of blood cells in mice (left). Mice treated with the PTP-sigma inhibitor displayed rapid recovery of blood cells (purple, right). Credit: UCLA Broad Stem Cell Research Center/Nature Communications

News | Radiation Therapy | August 16, 2019
A drug developed by UCLA physician-scientists and chemists speeds up the regeneration of mouse and human blood stem...
Mevion and C-RAD Release Integration for Improved Proton Therapy Treatment Quality

Catalyst PT image courtesy of C-RAD

News | Patient Positioning Radiation Therapy | August 15, 2019
Mevion Medical Systems and C-RAD announced the integration between the C-RAD Catalyst PT and the Mevion S250i proton...
First Patient Enrolled in World's Largest Brain Cancer Clinical Trial
News | Radiation Therapy | August 15, 2019
Henry Ford Cancer Institute is first-in-the-world to enroll a glioblastoma patient in the GBM AGILE Trial (Adaptive...
Efficacy of Isoray's Cesium Blu Showcased in Recent Studies
News | Brachytherapy Systems | August 14, 2019
August 14, 2019 — Isoray announced a trio of studies recently reported at scientific meetings and published in medica